GLP-1s May Offer Benefit in Ulcerative Colitis, Real-World Data Suggest
(MedPage Today) -- The use of GLP-1 receptor agonists was linked to improved remission rates in patients with ulcerative colitis, a retrospective cohort study suggested. Among 300 patients with ulcerative colitis, use of liraglutide (Victoza...
A retrospective study of 300 ulcerative colitis patients found those using GLP-1 receptor agonists such as liraglutide (Victoza, Saxenda) or semaglutide (Ozempic, Wegovy) for metabolic reasons experienced higher remission rates at 4, 8, and 12 weeks compared to those who did not use the drugs (34.7% vs 15.3%, 54.7% vs 18%, and 66.7% vs 25.3%, respectively).
When adjusted for various factors, the use of GLP-1 drugs was strongly associated with symptomatic remission (adjusted OR 5.90, 95% CI 3.52-9.86, P 0.001). Semaglutide showed a modest advantage over liraglutide in achieving symptomatic remission at 12 weeks (72.5% compared to 60%). Importantly, clinical improvement occurred before significant weight loss, suggesting a potential weight-independent anti-inflammatory effect.
The findings support a potential role for GLP-1 receptor agonists as an adjunctive therapy in ulcerative colitis, although further prospective studies, including randomized controlled trials, are needed to confirm these results.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
